TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07401381: A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Sponsor: Rovi Pharmaceuticals Laboratories · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,230,536

Rescue Site Savings

+$1,476,552

Unlock Full NCT07401381 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07401381 Rescue Dossier →